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Abstract
Objectives: MMP-9 and -12 function in tissue remodeling and may play roles in cardiovascular disease (CVD). We assessed
associations of four MMP polymorphisms and three antihypertensive drugs with cardiovascular outcomes.
Methods: Hypertensives (n=42,418) from a double-blind, randomized, clinical trial were randomized to chlorthalidone,
amlodipine, lisinopril, or doxazosin treatment (mean follow up, 4.9 years). The primary outcome was coronary heart disease
(CHD). Secondary outcomes included combined CHD, all CVD outcomes combined, stroke, heart failure (HF), and mortality.
Genotype-treatment interactions were tested.
Results: There were 38,698 participants genotyped for at least one of the polymorphisms included here. For MMP9 R668Q
(rs2274756), lower hazard ratios (HRs) were found for AA subjects for most outcomes when treated with chlorthalidone
versus amlodipine (eg., CCHD: GG=1.00, GA=1.01, AA=0.64; P=0.038). For MMP9 R279Q (rs17576), modest
pharmacogenetic findings were observed for combined CHD and the composite CVD outcome. For MMP12 N122S
(rs652438), lower HRs were observed for CHD in subjects carrying at least one G allele and being treated with chlorthalidone
versus lisinopril (CHD: AA=1.07, AG=0.80, GG=0.49; P=0.005). In the lisinopril-amlodipine comparison, higher HRs were
observed for participants having at least one G allele at the MMP12 N122S locus (CHD: AA=0.94, AG=1.19, GG=1.93;
P=0.041). For MMP12 282A.G (rs2276109), no pharmacogenetic effect was found for the primary outcome, although
lower HRs were observed for AA homozygotes in the chlorthalidone-amlodipine comparison for HF (P=0.015).
Conclusions: We observed interactions between antihypertensive drugs and MMP9 and MMP12 for CHD and composite
CVD. The data suggest that these genes may provide useful clinical information with respect to treatment decisions.
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Introduction
Matrix metalloproteinases (MMPs) are zinc-dependent endo-
peptidases which play a role in connective tissue remodeling.
Circulating levels of MMPs are associated with many cardiovas-
cular diseases (CVDs), including atherosclerosis, myocardial
infarction (MI), and heart failure [1,2,3]. MMP-9 (gelatinase-B)
functions in the degradation of type IV and V collagens, and its
levels are raised in individuals with hypertension, acute coronary
syndrome, and acute MI [2,4,5]. MMP-12, (macrophage metal-
loelastase) is up-regulated in atherosclerotic lesions and aneurysms
and may contribute to the activation of other MMPs, which, in
turn, degrade other extracellular matrix proteins [6]. A recent
study found that MMP-12 production by macrophages plays a role
in the transition from fatty acids to fibrous plaques during the
progression of atherosclerosis [7]. Given MMPs’ associations and
possible causal connections with CVD, these enzymes represent
potential drug targets for CVD treatment and prevention. In fact,
amlodipine and lercanidipine have been shown to influence
MMP-9 plasma levels and activity [8,9,10]. ACE inhibitors may
also affect MMP levels [11,12,13,14]. Attempts have been made to
assess associations of MMP gene variants with disease and risk
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the MMP9 279Q allele had higher plasma levels of MMP-9 and
higher risk of cardiovascular events than patients homozygous for
the 279R allele (P=0.02) [16]. The MMP9 R279Q polymor-
phism is a glutamine to arginine substitution located in the
catalytic domain of MMP-9 [16,20] and plausibly represents a
loss-of-function mutation [21]. The R668Q variant of MMP9 lies
within exon 12. This missense mutation lies in the hemopexin-like
domain and probably functions in substrate binding [19]. The
MMP12 282A.G variant, which lies in the gene’s promoter
region, affects transcription factor binding affinity, with the A
allele associated with increased promoter activity [15,18]; this
variant has been shown to affect coronary artery luminal
diameter [15]. The MMP12 N122S variant lies within the gene’s
coding region; although this variant has been associated with
endpoints such as breast cancer prognosis [22] and diabetic
nephropathy [23], the functional significance of the single-
nucleotide polymorphism (SNP) is unknown. Given these and
other MMP genetic associations with cardiovascular phenotypes
and known molecular interactions between antihypertensive
drugs and some MMPs, MMP genes may modify rates of CVD
outcomes differently for different antihypertensive treatments. We
tested whether hypertensive participants in the Genetics of
Hypertension Associated Treatment (GenHAT) Study genotyped
for MMP9 variants R279Q and R668Q and for MMP12 variants
N122S and 282A.G and randomized to either the diuretic
chlorthalidone, the calcium channel blocker amlodipine (CCB),
or the angiotensin converting enzyme (ACE) inhibitor lisinopril
had different outcome rates with regard to six CVD phenotypes.
(The doxazosin treatment arm was not included in the
pharmacogenetic analyses. See below.) All three of these drugs
are known to effectively lower blood pressure and all three are
commonly prescribed. The effect of treatment assignment on
CVD outcomes has been previously published [24,25]. We
sought to determine whether genotype for these variants
interacted with treatment assignment to produce a pharmacoge-
netic association with CVD outcomes.
Methods
Ethics statement
Participants recruited during the parent Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT) signed informed consent documents; the GenHAT
study was approved by the University of Minnesota Institutional
Review Board, the University of Alabama at Birmingham
Institutional Review Board for Human Use, and the University
of Texas Health Science Center at Houston Committee for the
Protection of Human Subjects.
Study Population
Study participants were part of the GenHAT study, the primary
objective of which was to determine whether variants in
hypertension susceptibility genes interact with antihypertensive
drugs to modify coronary heart disease risk in hypertensive
patients [26]. GenHAT is ancillary to the ALLHAT study, a
randomized, double-blind clinical trial examining 42,418 hyper-
tensive patients age 55 or older (47% non-White and 46% female)
with one or more risk factors for CVD. Participants were
randomized to one of four ALLHAT treatment arms—chlorthal-
idone, lisinopril, amlodipine, and doxazosin, in a ratio of 1.7:1:1:1,
respectively [26]. Due to early discontinuation of the doxazosin
arm of ALLHAT [27]—and thus fewer clinical outcomes in
genotype and treatment groups—we have not included the
doxazosin group in these analyses. The drug doses were titrated
to achieve blood pressures lower than 140/90 mmHg. Detailed
descriptions of both ALLHAT and GenHAT have been published
elsewhere [26,28].
GenHAT genotyped variants in several hypertension-related
genes in the 39,114 ALLHAT participants with available DNA,
making the study design a post-hoc subgroup analysis of a
randomized clinical trial [29]. Participants were excluded from
analysis if they were missing genotype data (n=489 for MMP9
R279Q, n=499 for MMP9 R668Q, n=1019 for MMP12 N122S,
n=577 for MMP12 282A.G). There were 38,698 participants
successfully genotyped for at least one of the polymorphisms
included in this analysis.
Outcomes
The primary outcome for both ALLHAT and GenHAT was
coronary heart disease (CHD), defined as fatal CHD or nonfatal
myocardial infarction (MI). Secondary outcomes for this study
included all-cause mortality (ACM); stroke; chronic heart failure
(CHF); combined CHD outcomes (CCHD, defined as CHD death
or non-fatal MI plus revascularization procedures plus hospitalized
angina); and combined CVD (CCVD, defined as CHD death or
non-fatal MI plus stroke, revascularization procedures, angina [in
hospital or outpatient], heart failure [in hospital or outpatient],
stroke, and peripheral arterial disease). Outcomes were reported
by the clinical investigator and supported, when possible, by death
certificates and hospitalization records. For a more detailed
description of ALLHAT outcomes, see Davis et al. [28].
Genotyping
Anonymized samples containing DNA were collected on FTA
paper (Fitzco Inc., Maple Plain, MN) and processed as described
by Arnett et al. [26]. Genotyping was performed using a
multiplex PCR and a linear immobilized probe research assay
for candidate markers (Roche Molecular Systems, Pleasanton,
CA, USA) as described by Burns et al. [30]. GenHAT genotyped
two SNPs in MMP9 (R279Q, rs17576 and R668Q, rs2274756)
and two SNPs in MMP12 (N122S, rs652438 and 282A.G,
rs2276109). The polymorphisms were genotyped in the context of
a larger panel of variants selected by the assay’s designer as
candidates for cardiovascular disease. Genotyping QC was
accomplished by preparing a set of 10 trays of replicate DNA
samples (n=767; 2% of GenHAT cohort) which were genotyped
along with the others. For the four variants reported on here,
correspondence between replicate genotype calls ranged from
97.6% to 99.1%.
Statistical analysis
STATA version 9.2 (STATA Corporation, College Station,
TX) was used for all analyses. Hardy-Weinberg equilibrium
(HWE) tests were performed using chi-square tests. To test for
baseline differences between treatment groups, we used ANOVA
for continuous variables and chi-square tests for categorical
variables. Cox proportional regression was used for testing the
main effects of MMP genotypes on the outcomes as well as the
genotype-by-treatment interactions (the pharmacogenetic effects),
resulting in hazard ratios (HR) and ratios of hazard ratios point
estimates, respectively. To test the main effects of the genotypes on
the outcomes, we adjusted for age; gender; ethnicity (Hispanic
status); race (5 self-reported categories: White, Black, American
Indian/Alaskan native, Asian/Pacific Islander, and ‘‘other’’);
smoking status; diabetes status; aspirin use; and baseline values
for body mass index (BMI), systolic and diastolic blood pressures,
and HDL and LDL cholesterol. To test for genotype-by-treatment
CVD Pharmacogenetics of MMP9 and MMP12
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Characteristic Chlorthalidone Amlodipine Lisinopril Doxazosin P-value*
Sample size, n (%) by treatment 13,928 (36.0) 8,243 (21.3) 8,273 (21.4) 8,254 (21.3)
Age (y) 66.8 (7.7) 66.9 (7.7) 66.8 (7.8) 66.7 (7.7) 0.74
Race
White, n (col %) 8,451 (60.7) 4,999 (60.7) 5,025 (60.7) 4,976 (60.3)
Black, n (col %) 4,770 (34.3) 2,859 (34.7) 2,839 (34.3) 2,890 (35.0)
American Indian/Alaskan native, n (col %) 26 (0.2) 19 (0.2) 18 (0.2) 10 (0.1)
Asian/Pacific Islander, n (col %) 170 (1.2) 97 (1.2) 85 (1.0) 95 (1.2)
Other, n (col %) 511 (3.7) 269 (3.3) 306 (3.7) 283 (3.4) 0.64
Hispanic, n (%) 2,722 (19.5) 1,558 (18.9) 1,639 (19.8) 1,618 (19.6) 0.86
Women, n (%) 6,552 (47.0) 3,926 (47.6) 3,831 (46.3) 3,817 (46.2) 0.22
Previous antihypertensive treatment, n (%) 12,571 (90.3) 7,472 (90.7) 7,454 (90.1) 7,447 (90.2) 0.66
Blood pressure at baseline, mm Hg
All participants
SBP 146.2 (15.7) 146.2 (15.7) 146.5 (15.6) 146.3 (15.8) 0.67
DBP 84.1 (10.0) 83.9 (10.2) 84.1 (10.0) 83.9 (10.0) 0.41
Treated at baseline
SBP 145.2 (15.6) 145.1 (15.6) 145.4 (15.5) 145.2 (15.7) 0.75
DBP 83.5 (10.0) 83.3 (10.1) 83.6 (9.9) 83.4 (9.9) 0.30
Untreated at baseline
SBP 156.1 (12.0) 156.6 (12.2) 156.4 (12.3) 156.8 (12.5) 0.57
DBP 89.5 (9.0) 89.7 (9.5) 89.1 (9.3) 89.4 (9.5) 0.63
Eligibility risk factors
Current cigarette smoker, n (%) 3,061 (22.0) 1,810 (22.0) 1,817 (22.0) 1,795 (21.8) 0.98
Type 2 diabetes, n (%) 4,983 (35.8) 3,008 (36.5) 2,899 (35.0) 2,891 (35.0) 0.15
HDL cholesterol ,35 mg/dL, n (%) 1,666 (12.0) 939 (11.4) 976 (11.8) 973 (11.8) 0.65
LVH by electrocardiogram, n (%) 2,255 (16.2) 1,398 (17.0) 1,342 (16.2) 1,354 (16.4) 0.47
Body mass index, kg/m
2 29.7 (6.1) 29.8 (6.3) 29.8 (6.2) 29.7 (5.9) 0.32
Fasting glucose, mg/dL 123.4 (58.6) 123.1 (57.5) 122.4 (55.6) 121.9 (55.9) 0.35
LDL cholesterol, mg/dL 136.0 (37.3) 135.7 (37.3) 135.8 (36.4) 135.2 (36.3) 0.60
HDL cholesterol, mg/dL 46.8 (14.9) 47.2 (14.7) 46.6 (14.6) 46.6 (14.4) 0.04
Fasting triglycerides, mg/dL 176.7 (130.9) 176.6 (132.8) 175.5 (138.5) 174.1 (137.6) 0.53
Aspirin use, n (%) 4,986 (35.8) 3,002 (36.4) 3,021 (36.5) 3,026 (36.7) 0.54
MMP9 R279Q (A.G) (rs17576)
AA 5,955 (42.8) 3,422 (41.6) 3,596 (43.6) 3,550 (43.1)
AG 6,257 (45.0) 3,783 (46.0) 3,633 (44.0) 3,675 (44.6)
GG 1,691 (12.2) 1,026 (12.5) 1,024 (12.4) 1,013 (12.3) 0.21
MMP9 R668Q (G.A) (rs2274756)
GG 10,004 (72.0) 5,827 (70.8) 5,916 (71.7) 5,939 (72.1)
GA 3,564 (25.7) 2,196 (26.7) 2,121 (25.7) 2,085 (25.3)
AA 326 (2.4) 207 (2.5) 219 (2.7) 211 (2.6) 0.33
MMP12 282A.G (rs2276109)
AA 11,648 (84.0) 6,899 (84.0) 6,903 (83.8) 6,926 (84.3)
AG 2,083 (15.0) 1,242 (15.1) 1,269 (15.4) 1,216 (14.8)
GG 137 (1.0) 68 (0.8) 68 (0.8) 78 (1.0) 0.74
MMP12 N122S (A.G) (rs652438)
AA 11,029 (80.6) 6,562 (80.8) 6,652 (81.5) 6,565 (80.8)
AG 2,423 (17.7) 1,415 (17.4) 1,400 (17.2) 1,426 (17.6)
GG 235 (1.7) 145 (1.8) 111 (1.4) 132 (1.6) 0.31
SBP=systolic blood pressure, DBP=diastolic blood pressure, LVH=left ventricular hypertrophy.
*test of differences between genotype groups: ANOVA for continuous variables, chi-square for categorical variables.
doi:10.1371/journal.pone.0023609.t001
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three separate comparisons: chlorthalidone versus amlodipine,
chlorthalidone versus lisinopril, and lisinopril versus amlodipine.
We tested three genetic models for the pharmacogenetic effects:
additive (3 genotype categories with a 2 degrees of freedom [df]
interaction test), dominant (collapsing minor homozygote group
with heterozygote group resulting in 2 genotype groups with a 1 df
interaction test), and recessive (collapsing common homozygote
group with heterozygote group resulting in 2 genotype groups with
a 1 df interaction test).
The previously published GenHAT design paper outlined six
primary, a priori hypotheses; however, these hypotheses did not
include testing the pharmacogenetic effect of MMP9 or MMP12
variants. Therefore, secondary investigations such as this MMP
study are considered exploratory and, as such, are not adjusted for
multiple comparisons. Since we performed multiple statistical tests
of the pharmacogenetic effects of MMP9 and MMP12 variants,
caution must be exercised in pronouncing any findings reported
here as statistically significant.
Results
Table 1 shows the baseline characteristics of the study subjects
(n=38,698, participants with at least one variant included in these
analyses). There were no significant differences between groups
except for HDL cholesterol (P=0.04), which was higher in those
randomized to amlodipine versus chlorthalidone or lisinopril.
The MMP9 R279Q and MMP12 282A.G genotype frequencies
were in Hardy-Weinberg equilibrium (HWE) when tested within
Table 2. Main effects of MMP genetic variants on clinical outcomes, all treatments combined.
Number of events (event rate per 1000 p-y) Adjusted* Hazard Ratios (95% CI)
Genotype CHD CCHD CCVD ACM Stroke CHF CHD CCHD CCVD ACM Stroke CHF
MMP9 R279Q (rs17576)
AA 1373 2573 4368 2268 777 1149 1.00 1.00 1.00 1.00 1.00 1.00
(19.0) (37.3) (68.1) (29.0) (10.6) (15.9)
GA 1478 2738 4529 2319 731 1158 1.00 1.01 0.97 0.96 0.87 0.92
(19.5) (37.8) (67.2) (28.1) (9.5) (15.3) (0.93–1.08) (0.96–1.07) (0.93–1.02) (0.90–1.02) (0.79–0.97) (0.85–1.00)
GG 420 767 1275 618 202 347 1.00 1.01 0.99 0.93 0.91 1.02
(20.3) (38.9) (69.3) (27.4) (9.6) (16.8) (0.90–1.14) (0.93–1.10) (0.93–1.06) (0.85–1.02) (0.78–1.07) (0.90–1.16)
P 0.99 0.92 0.51 0.20 0.04 0.10
MMP9 R668Q (rs2274756)
GG 2360 4376 7311 3738 1240 1897 1.00 1.00 1.00 1.00 1.00 1.00
(19.6) (38.0) (68.3) (28.5) (10.2) (15.7)
GA 817 1538 2579 1323 425 688 0.95 0.97 0.97 0.97 0.94 0.99
(18.6) (36.6) (66.1) (27.7) (9.5) (15.7) (0.87–1.03) (0.92–1.04) (0.93–1.02) (0.91–1.03) (0.84–1.06) (0.90–1.09)
AA 94 164 275 133 45 67 1.15 1.10 1.06 0.96 0.99 1.00
(22.4) (41.0) (74.0) (29.3) (10.5) (16.0) (0.93–1.43) (0.93–1.29) (0.94–1.21) (0.80–1.15) (0.72–1.35) (0.77–1.29)
P 0.16 0.34 0.31 0.59 0.61 0.98
MMP12 282A.G (rs2276109)
AA 2692 4991 8409 4409 1445 2161 1.00 1.00 1.00 1.00 1.00 1.00
(19.1) (37.0) (67.0) (28.7) (10.1) (15.3)
AG 535 1008 1624 736 245 449 0.97 0.96 0.96 0.93 1.00 1.05
(20.8) (41.4) (71.9) (26.5) (9.4) (17.5) (0.88–1.08) (0.90–1.04) (0.91–1.02) (0.85–1.01) (0.86–1.15) (0.94–1.18)
GG 35 67 116 47 19 32 0.99 1.00 1.12 0.97 1.32 1.26
(22.4) (45.2) (87.3) (27.9) (12.0) (20.6) (0.68–1.42) (0.77–1.29) (0.92–1.36) (0.71–1.32) (0.81–2.13) (0.86–1.83)
P 0.87 0.63 0.24 0.20 0.53 0.36
MMP12 N122S (rs652438)
AA 2651 4969 8210 4143 1334 2126 1.00 1.00 1.00 1.00 1.00 1.00
(19.7) (38.7) (68.8) (28.4) (9.8) (15.8)
AG 503 911 1621 893 321 432 0.95 0.95 0.96 0.98 1.10 0.97
(17.2) (32.4) (61.9) (28.2) (10.9) (14.9) (0.86–1.05) (0.88–1.02) (0.91–1.02) (0.91–1.06) (0.96–1.25) (0.87–1.09)
GG 60 102 169 82 29 45 1.36 1.31 1.14 0.95 1.01 1.13
(22.5) (40.1) (71.2) (27.3) (10.7) (16.7) (1.04–1.79) (1.06–1.62) (0.96–1.34) (0.76–1.20) (0.68–1.49) (0.83–1.55)
P 0.04 0.01 0.12 0.83 0.39 0.64
CHD, coronary heart disease defined as fatal CHD or nonfatal myocardial infarction; CCHD, combined CHD defined as CHD death or non-fatal myocardial infarction plus
revascularization procedures plus hospitalized angina; CCVD, combined cardiovascular disease defined as CHD death or non-fatal MI plus stroke, revascularization
procedures, angina, heart failure, stroke, and peripheral arterial disease; ACM, all-cause mortality; CHF, .chronic heart failure.
*adjusted for age, sex, race, Hispanic status, smoking status, diabetes status, aspirin use, and baseline values for BMI, SBP, DBP, HDL- and LDL-cholesterol.
doi:10.1371/journal.pone.0023609.t002
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were in HWE equilibrium for the Black, American Indian/Alaskan
native, Asian/Pacific islander, and ‘‘other’’ groups, but not for the
White group (P=0.04). After stratifying Whites by Hispanic status,
the MMP9 R 6 6 8 Qg e n o t y p ef r e q u e n c i e sw e r ei nH W Ef o rn o n -
Hispanic Whites, but not for Hispanic Whites (P=0.001). The
MMP12 N122S genotype frequencies were in HWE for the Asian/
Pacific islander and ‘‘other’’ groups, but not for the Black or White
groups. The American Indian/Alaskan native group included no
minorMMP12 N122S homozygotes (ie, GG). After stratifying Whites
and Blacks by Hispanic status, MMP12 N122S genotype frequencies
were in HWE for all groups except Black non-Hispanics (P=0.0003).
MaineffectsofMMP9andMMP12variantsonclinicaloutcomes
The effects of ALLHAT treatment assignments on CVD
outcomes have been published elsewhere [24,25,27]. Hazard
ratios for main effects of genetic variants on ALLHAT clinical
outcomes in GenHAT are shown in Table 2. After adjusting for
baseline characteristics, the association between the MMP9
R279Q variant and stroke was modestly significant, with
participants carrying the minor G allele having decreased risk of
stroke (HR=1.00 for AA, 0.87 for GA, 0.91 for GG; P=0.04,
additive genetic model). The associations between the MMP12
N122S variant and CHD and CCHD were also modestly
significant (P=0.04 and P=0.01, respectively), with participants
with the minor allele homozygote (GG) genotype having a 30%
increased risk of CHD or CCHD compared to participants having
the common AA genotype (for CHD HR=1.00 for AA, 0.95 for
AG, 1.36 for GG; P=0.04; for CCHD HR=1.00 for AA, 0.95 for
AG, 1.31 for GG; P=0.01). The effects of the MMP9 R668Q and
MMP12 282A.G variants were not significant for any outcome.
Pharmacogenetic effects of MMP9 and MMP12 variants
on clinical outcomes
Tables 3, 4, 5, 6, 7, 8 show ALLHAT clinical outcome
frequencies and rates by genotype and treatment group for CHD,
Table 3. Pharmacogenetic effects of MMP genetic variants on CHD.
Number of events (Event rate per
1000 p-y)
Genotype-specific treatment effects
(Hazard Ratio (95% CI)) Pharmacogenetic effects*
Genotype CHL AML LIS C vs. A C. vs. L L vs. A C vs. A C. vs. L L vs. A
MMP9 R279Q (rs17576)
AA 544 285 311 1.12 1.06 1.06 PA=0.11 PA=0.18 PA=0.56
(20.0) (17.9) (18.9) (0.97–1.29) (0.92–1.21) (0.90–1.24)
AG 550 343 307 0.97 1.03 0.94 PD=0.07 PD=0.39 PD=0.38
(19.0) (19.7) (18.5) (0.84–1.11) (0.89–1.18) (0.81–1.10)
GG 137 100 101 0.84 0.81 1.04 PR=0.13 PR=0.07 PR=0.78
(17.7) (21.1) (22.0) (0.65–1.08) (0.62–1.04) (0.79–1.37)
MMP9 R668Q (rs2274756)
GG 902 523 517 1.01 1.02 0.98 PA=0.13 PA=0.45 PA=0.61
(19.7) (19.5) (19.2) (0.91–1.12) (0.92–1.14) (0.87–1.11)
GA 303 177 180 1.07 0.99 1.08 PD=0.97 PD=0.53 PD=0.60
(18.3) (17.2) (18.6) (0.89–1.29) (0.82–1.19) (0.88–1.33)
AA 25 27 24 0.59 0.74 0.84 PR=0.05 PR=0.22 PR=0.50
(16.9) (28.5) (23.8) (0.34–1.02) (0.42–1.30) (0.48–1.46)
MMP12 282A.G (rs2276109)
AA 1006 610 591 0.98 1.00 0.98 PA=0.52 PA=0.19 PA=0.13
(18.8) (19.2) (18.8) (0.88–1.08) (0.90–1.10) (0.88–1.10)
AG 200 108 125 1.14 0.98 1.16 PD=0.25 PD=0.77 PD=0.44
(20.9) (18.4) (21.3) (0.90–1.44) (0.79–1.23) (0.89–1.50)
GG 18 9 3 1.00 3.25 0.33 PR=0.96 PR=0.07 PR=0.10
(28.9) (28.3) (9.3) (0.45–2.22) (0.96–11.0) (0.09–1.22)
MMP12 N122S (rs652438)
AA 1003 593 563 1.01 1.07 0.94 PA=0.91 PA=0.005 PA=0.041
(19.8) (19.6) (18.5) (0.91–1.12) (0.97–1.19) (0.84–1.06)
AG 182 113 128 0.96 0.80 1.19 PD=0.66 PD=0.005 PD=0.037
(16.3) (17.0) (20.3) (0.76–1.21) (0.64–1.01) (0.93–1.54)
GG 21 13 19 0.97 0.49 1.93 PR=0.89 PR=0.019
(19.7) (20.6) (40.9) (0.48–1.93) (0.26–0.91) (0.95–3.92)
PA=P-value for additive genetic model, PD=P-value for dominant genetic model, PR=P-value for recessive genetic model.
*P-value for gene-by-treatment interaction.
CHD, coronary heart disease defined as fatal CHD or nonfatal myocardial infarction; CHL, chlorthalidone treatment group; AML, amlodipine treatment group; LIS,
lisinopril treatment group.
doi:10.1371/journal.pone.0023609.t003
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are genotype-specific treatment effects and gene-by-treatment
interaction P-values for chlorthalidone versus amlodipine, chlor-
thalidone versus lisinopril, and lisinopril versus amlodipine.
Treatment effects differed by genotype for several outcomes.
CHD, combined CHD, and combined CVD. Participants
having the MMP9 R668Q minor allele homozygote (AA) genotype
had lower risk of CCHD when randomized to chlorthalidone
versus amlodipine (HR=0.64). No significant differences in CHD
or CCHD were observed across AG or GG genotype-treatment
groups. The P-value for the pharmacogenetic effect for CCHD in
the recessive genetic model was 0.038.
Subjects with the MMP9 R279Q GG genotype had lower risk of
CCVD when randomized to chlorthalidone versus amlodipine or
lisinopril (HR=0.81 and 0.78, respectively) compared with
participants with at least one copy of the A allele (pharmacogenetic
effect P=0.024 and P=0.026 for chlorthalidone versus amlodi-
pine and chlorthalidone versus lisinopril, respectively in recessive
models). A similar effect was observed for the CCHD outcome,
with only the chlorthalidone versus lisinopril comparison reaching
a P-value,0.05 (P=0.045 for the recessive model).
Participants having the MMP12 N122S variant GG genotype had
significantly increased rates (40.9 per 1000 p-y) of CHD if taking
lisinopril versus any other genotype-treatment combination (16.3–
20.6 per 1000 p-y). This difference led to a detectable pharmaco-
genetic effect for both chlorthalidone versus lisinopril and lisinopril
versus amlodipine comparisons (P-values for pharmacogenetic effect
ranged from 0.005 to 0.041 depending on genetic model). Results for
CCHD and CCVD were consistent with this observation.
For the MMP12 282A.G variant, there was evidence of a
pharmacogenetic effect on CCVD for the chlorthalidone versus
lisinopril comparison. Homozygotes for the minor G allele had
increased risk of CCVD when randomized to chlorthalidone
versus lisinopril (HR=1.75), while the common A allele carriers
had slightly reduced risk (HR=0.90 for AA group, HR=0.95 for
AG group; pharmacogenetic effect P=0.025).
Table 4. Pharmacogenetic effects of MMP genetic variants on CCHD.
Number of events (event rate per
1000 p-y)
Genotype-specific treatment effects:
Hazard Ratio (95% CI) Pharmacogenetic effects*
Genotype CHL AML LIS C vs. A C. vs. L L vs. A C vs. A C. vs. L L vs. A
MMP9 R279Q (rs17576)
AA 952 556 569 1.00 1.01 0.99 PA=0.22 PA=0.12 PA=0.71
(36.5) (36.6) (36.3) (0.90–1.11) (0.91–1.12) (0.88–1.11)
AG 1022 602 599 1.03 0.97 1.06 PD=0.91 PD=0.29 PD=0.40
(37.2) (36.1) (38.1) (0.93–1.14) (0.88–1.08) (0.94–1.18)
GG 256 182 186 0.85 0.81 1.06 PR=0.09 PR=0.045 PR=0.78
(34.5) (40.6) (42.9) (0.70–1.03) (0.67–0.97) (0.86–1.30)
MMP9 R668Q (rs2274756)
GG 1615 946 970 1.00 0.97 1.03 PA=0.12 PA=0.30 PA=0.84
(36.9) (36.9) (37.9) (0.92–1.08) (0.90–1.05) (0.94–1.12)
GA 565 350 346 1.01 0.96 1.05 PD=0.65 PD=0.54 PD=0.89
(35.9) (35.7) (37.6) (0.88–1.15) (0.84–1.09) (0.91–1.22)
AA 45 44 43 0.64 0.71 0.93 PR=0.038 PR=0.13 PR=0.60
(31.6) (49.2) (45.4) (0.42–0.97) (0.47–1.08) (0.61–1.42)
MMP12 282A.G (rs2276109)
AA 1817 1109 1120 0.97 0.95 1.03 PA=0.48 PA=0.18 PA=0.76
(35.5) (36.5) (37.6) (0.90–1.05) (0.88–1.02) (0.95–1.12)
AG 370 218 226 1.04 1.00 1.04 PD=0.35 PD=0.31 PD=0.95
(40.8) (39.3) (40.8) (0.88–1.23) (0.85–1.18) (0.86–1.25)
GG 32 12 9 1.35 1.91 0.72 PR=0.33 PR=0.08 PR=0.46
(54.1) (39.4) (29.1) (0.70–2.63) (0.91–4.01) (0.30–1.71)
MMP12 N122S (rs652438)
AA 1831 1092 1092 1.00 1.00 1.00 PA=0.45 PA=0.023 PA=0.14
(38.0) (37.8) (37.8) (0.93–1.08) (0.93–1.08) (0.92–1.09)
AG 319 209 227 0.90 0.79 1.15 PD=0.39 PD=0.008 PD=0.10
(29.7) (32.9) (37.7) (0.76–1.07) (0.66–0.93) (0.95–1.38)
GG 40 20 24 1.18 0.74 1.58 PR=0.52 PR=0.29 PR=0.14
(39.1) (33.1) (53.5) (0.69–2.01) (0.45–1.23) (0.87–2.85)
PA=P-value for additive genetic model, PD=P-value for dominant genetic model, PR=P-value for recessive genetic model.
*P-value for gene-by-treatment interaction.
CCHD, combined CHD defined as CHD death or non-fatal myocardial infarction plus revascularization procedures plus hospitalized angina; CHL, chlorthalidone
treatment group; AML, amlodipine treatment group; LIS, lisinopril treatment group.
doi:10.1371/journal.pone.0023609.t004
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genotypes experienced substantially increased ACM (39% and
28%, respectively) on lisinopril compared to those on amlodipine,
while no differences in ACM were found with the common AA
genotype-treatment combinations. The P-value for the
pharmacogenetic effect was 0.013 when modeled additively and
0.004 when modeled dominantly. For the chlorthalidone versus
amlodipine comparison, GG participants had reduced risk on
chlorthalidone (HR=0.81), while AG heterozygotes had increased
risk (HR=1.32). There was no treatment effect among the
common AA homozygotes (HR=1.01). The P-value for this
pharmacogenetic effect was 0.021 when modeled additively.
Subjects having the MMP12 282A.G GG genotype had
significantly lower ACM on lisinopril versus amlodipine
(HR=0.37), while those with at least one copy of the A allele had
somewhat higher risk on lisinopril versus amlodipine (HR=1.07
and 1.12 for AA and AG groups, respectively; P=0.043 for the
pharmacogenetic effect when modeled recessively).
Stroke. Those subjects having MMP9 R668Q common GG
genotype randomized to chlorthalidone had a slightly increased
risk of stroke over those with the same genotype randomized to
amlodipine (HR=1.08), whereas participants with the AA
genotype had a 3.65-fold increased risk of stroke when
randomized to chlorthalidone versus amlodipine. There was no
treatment effect among heterozygotes (HR=0.99). The P-value
for the pharmacogenetic effect was marginally significant
(P=0.048).
HF. A pharmacogenetic effect is suggested for the MMP12
282A.G polymorphism with both the chlorthalidone versus
amlodipine group and the chlorthalidone versus lisinopril group
comparisons. All subjects with data for the MMP12 282A.G
polymorphism, regardless of genotype, showed decreased risk of HF
onchlorthalidone versus amlodipine.However,therewas a stronger
protective effect of chlorthalidone versus amlodipine among those
with the common AA genotype compared to G allele carriers
(HR=0.67 for AA group, HR=0.95 for AG group, HR=0.77 for
Table 5. Pharmacogenetic effects of MMP genetic variants on CCVD.
Number of events (event rate per
1000 p-y)
Genotype-specific treatment effects:
Hazard Ratio (95% CI) Pharmacogenetic effects*
Genotype CHL AML LIS C vs. A C. vs. L L vs. A C vs. A C. vs. L L vs. A
MMP9 R279Q (rs17576)
AA 1552 952 963 0.94 0.96 0.98 PA=0.038 PA=0.05 PA=0.15
(63.5) (67.6) (66.2) (0.87–1.02) (0.89–1.04) (0.90–1.07)
AG 1631 978 1012 1.01 0.91 1.11 PD=0.67 PD=0.10 PD=0.06
(63.4) (62.9) (70.0) (0.93–1.09) (0.84–0.98) (1.02–1.21)
GG 413 301 303 0.81 0.78 1.04 PR=0.024 PR=0.026 PR=0.98
(58.8) (72.5) (75.7) (0.70–0.94) (0.67–0.90) (0.89–1.22)
MMP9 R668Q (rs2274756)
GG 2602 1600 1617 0.94 0.93 1.01 PA=0.36 PA=0.33 PA=0.16
(63.4) (67.3) (68.1) (0.89–1.00) (0.88–0.99) (0.94–1.08)
GA 907 562 597 1.00 0.87 1.15 PD=0.52 PD=0.17 PD=0.07
(61.4) (61.3) (70.9) (0.90–1.11) (0.78–0.96) (1.03–1.29)
AA 82 65 69 0.80 0.78 1.02 PR=0.28 PR=0.35 PR=0.88
(61.9) (77.4) (78.9) (0.58–1.11) (0.56–1.07) (0.73–1.44)
MMP12 282A.G (rs2276109)
AA 2942 1857 1890 0.93 0.90 1.04 PA=0.21 PA=0.06 PA=0.35
(61.3) (65.7) (68.6) (0.88–0.99) (0.84–0.95) (0.98–1.11)
AG 588 343 371 1.05 0.95 1.10 PD=0.08 PD=0.16 PD=0.74
(69.4) (66.2) (72.8) (0.92–1.20) (0.84–1.09) (0.95–1.27)
GG 53 23 17 1.16 1.75 0.70 PR=0.41 PR=0.025 PR=0.19
(100.8) (85.9) (59.0) (0.71–1.90) (1.01–3.02) (0.37–1.31)
MMP12 N122S (rs652438)
AA 2903 1800 1822 0.96 0.94 1.02 PA=0.52 PA=0.06 PA=0.19
(64.2) (67.1) (68.3) (0.90–1.01) (0.89–1.00) (0.95–1.09)
AG 566 350 388 0.96 0.81 1.18 PD=0.76 PD=0.024 PD=0.08
(56.3) (58.8) (69.5) (0.84–1.09) (0.71–0.92) (1.02–1.36)
GG 59 44 37 0.76 0.70 1.10 PR=0.25 PR=0.19 PR=0.83
(60.9) (80.2) (88.6) (0.52–1.13) (0.46–1.05) (0.71–1.71)
PA=P-value for additive genetic model, PD=P-value for dominant genetic model, PR=P-value for recessive genetic model.
*P-value for gene-by-treatment interaction.
CCVD, combined cardiovascular disease defined as CHD death or non-fatal MI plus stroke, revascularization procedures, angina, heart failure, stroke, and peripheral
arterial disease; CHL, chlorthalidone treatment group; AML, amlodipine treatment group; LIS, lisinopril treatment group.
doi:10.1371/journal.pone.0023609.t005
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dominantly). Among those with the GG genotype, a 3.76-fold
increased risk of HF was found for those subjects randomized to
chlorthalidone vs. lisinopril, whereas for those with the common AA
genotype the risk of HF was reduced in the chlorthalidone group
versus the lisinopril group (HR=0.78). There was no difference in
treatment effect among AG heterozygotes (HR=0.98). Although
this pharmacogenetic effect is significant (P=0.040 for the additive
model, P=0.044 for the dominant model, P=0.048 for the
recessive model), it should be noted that there were few events
(n=2) in the GG genotype-lisinopril group.
Implications of Hardy-Weinberg disequilibrium
Because MMP12 N122S and MMP9 R668Q variants were not in
HWE for all ethnic subgroups, we tested whether the suggestive
pharmacogenetic effects would be similar if we omitted the
subgroups in HW disequilibrium. Therefore, for the MMP12
N122S analysis we omitted the Black-non-Hispanic participants
(31% of the overall population), and for the MMP9 R668Q analysis
we omitted the White-Hispanic participants (13% of the overall
population). The results of these analyses showed that for all the
findings presented in Tables 3, 4, 5, 6, 7, 8 for these two variants
with a P-value less than 0.05, the pharmacogenetic effect (ratio of
hazard ratios) was in the same direction and, for the most part, of
similar magnitude (data not shown). Due in part to reduced sample
sizes, the P-values varied inmost cases. In some cases the association
was slightly strengthened. In cases where association was attenuat-
ed, the most disparate finding when omitting the subgroup in HW
disequilibrium was found for the pharmacogenetic effect of the
MMP9 R668Q variant on combined CHD when comparing
chlorthalidone toamlodipine: forthefullgroup modeled recessively,
the ratio of hazard ratios was 0.64 (P=0.04), whereas it was 0.71
(P=0.13) when omitting the White-Hispanic group.
Discussion
In this study we evaluated the pharmacogenetic effects of
MMP9 and MMP12 variants on CHD, stroke, HF, combined
Table 6. Pharmacogenetic effects of MMP genetic variants on ACM.
Number of events (event rate per
1000 p-y)
Genotype-specific treatment effects: Hazard
Ratio (95% CI) Pharmacogenetic effects*
Genotype CHL AML LIS C vs. A C. vs. L L vs. A C vs. A C. vs. L L vs. A
MMP9 R279Q (rs17576)
AA 858 465 519 1.08 1.00 1.07 PA=0.72 PA=0.87 PA=0.76
(29.6) (27.5) (29.5) (0.96–1.21) (0.90–1.12) (0.95–1.22)
AG 883 510 526 1.04 0.97 1.08 PD=0.53 PD=0.67 PD=0.85
(28.6) (27.5) (29.6) (0.93–1.16) (0.87–1.08) (0.96–1.22)
GG 229 141 138 0.98 1.00 0.98 PR=0.50 PR=0.87 PR=0.46
(27.6) (28.0) (27.6) (0.79–1.21) (0.81–1.24) (0.77–1.24)
MMP9 R668Q (rs2274756)
GG 1420 790 859 1.05 0.97 1.08 PA=0.97 PA=0.83 PA=0.81
(29.1) (27.6) (29.8) (0.96–1.15) (0.89–1.06) (0.98–1.19)
GA 501 294 291 1.05 1.02 1.03 PD=0.94 PD=0.54 PD=0.55
(28.4) (27.0) (27.8) (0.91–1.21) (0.89–1.18) (0.87–1.21)
AA 47 30 32 1.00 1.06 0.96 PR=0.81 PR=0.87 PR=0.71
(30.0) (30.1) (29.7) (0.63–1.57) (0.67–1.66) (0.58–1.58)
MMP12 282A.G (rs2276109)
AA 1646 951 1008 1.03 0.96 1.07 PA=0.17 PA=0.19 PA=0.12
(28.9) (28.1) (29.9) (0.95–1.11) (0.89–1.04) (0.98–1.16)
AG 297 148 168 1.22 1.09 1.12 PD=0.19 PD=0.15 PD=0.94
(29.1) (24.0) (26.9) (1.00–1.49) (0.90–1.32) (0.90–1.40)
GG 21 14 5 0.74 2.04 0.37 PR=0.31 PR=0.16 PR=0.043
(30.8) (42.1) (15.1) (0.37–1.45) (0.77–5.42) (0.13–1.04)
MMP12 N122S (rs652438)
AA 1540 909 926 1.01 1.00 1.01 PA=0.021 PA=0.23 PA=0.013
(28.5) (28.3) (28.5) (0.93–1.10) (0.93–1.09) (0.92–1.10)
AG 365 164 220 1.32 0.95 1.39 PD=0.022 PD=0.33 PD=0.004
(30.7) (23.3) (32.3) (1.10–1.59) (0.80–1.12) (1.14–1.71)
GG 29 22 21 0.81 0.63 1.28 PR=0.35 PR=0.11 PR=0.52
(24.8) (30.9) (39.6) (0.47–1.42) (0.36–1.10) (0.70–2.32)
PA=P-value for additive genetic model, PD=P-value for dominant genetic model, PR=P-value for recessive genetic model.
*P-value for gene-by-treatment interaction.
ACM, all-cause mortality; CHL, chlorthalidone treatment group; AML, amlodipine treatment group; LIS, lisinopril treatment group.
doi:10.1371/journal.pone.0023609.t006
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pharmacogenetic associations between variants in the MMP9 and
MMP12 genes and treatment for a variety of these cardiovascular
outcomes: MMP9 R668Q variant for both combined CHD and
stroke; MMP9 R279Q variant for the combined CVD outcome;
and MMP12 N122S variant for CHD, combined CHD, combined
CVD, and ACM. Specifically, we found that patients having the
MMP9 R668Q AA genotype who were treated with chlorthali-
done have a decreased risk of combined CHD but an increased
risk of stroke compared to patients treated with amlodipine.
Patients with the MMP9 R279Q GG genotype treated with
chlorthalidone had lower risk of combined CVD than patients
treated with amlodipine or lisinopril. For those having either
MMP12 N122S AG or GG genotype, lisinopril treatment
increased the risk of CHD, combined CHD, and combined
CVD when compared to patients treated with chlorthalidone or a
higher risk of CHD and ACM when compared to patients treated
with amlodipine. In aggregate, these results indicate these variants
may be useful in selecting appropriate antihypertensive agents to
reduce risk of CVD.
Because some MMP12 and MMP9 variants were not in HWE
for all ethnic subgroups, we investigated whether the pharmaco-
genetic effects would be similar if we omitted the subgroups in HW
disequilibrium. These analyses showed that the pharmacogenetic
effect was in the same direction and of similar magnitude with the
reduced sample. We note that both the Black and Hispanic groups
likely had diverse ancestry given that participants were recruited in
the US, Canada, and the Caribbean; therefore, some degree of
population substructure is expected. However, it should be
emphasized that even if population substructure in the data leads
to HW disequilibrium, which can lead to an increase in false-
positive findings for main effects of genetic variants on outcomes, this
should not explain any pharmacogenetic findings because participants
were randomized to treatment; therefore, confounding from
population substructure should be controlled because randomiza-
tion in the context of a large sample size results in the same degree
Table 7. Pharmacogenetic effects of MMP genetic variants on stroke.
Number of events (event rate per
1000 p-y)
Genotype-specific treatment effects:
Hazard Ratio (95% CI) Pharmacogenetic effects*
Genotype CHL AML LIS C vs. A C. vs. L L vs. A C vs. A C. vs. L L vs. A
MMP9 R279Q (rs17576)
AA 288 146 180 1.15 0.96 1.20 PA=0.63 PA=0.29 PA=0.47
(10.4) (9.0) (10.8) (0.94–1.40) (0.80–1.16) (0.96–1.49)
AG 253 145 185 1.05 0.78 1.35 PD=0.41 PD=0.18 PD=0.68
(8.6) (8.2) (11.1) (0.86–1.29) (0.65–0.94) (1.08–1.67)
GG 70 45 45 0.95 0.93 1.02 PR=0.46 PR=0.75 PR=0.34
(8.9) (9.4) (9.6) (0.65–1.38) (0.64–1.35) (0.68–1.55)
MMP9 R668Q (rs2274756)
GG 456 247 286 1.08 0.93 1.16 PA=0.12 PA=0.16 PA=0.15
(9.8) (9.1) (10.5) (0.93–1.26) (0.81–1.08) (0.98–1.37)
GA 139 87 114 0.99 0.71 1.39 PD=0.99 PD=0.10 PD=0.15
(8.3) (8.4) (11.6) (0.76–1.30) (0.56–0.92) (1.05–1.84)
AA 17 3 11 3.65 1.04 3.50 PR=0.048 PR=0.62 PR=0.11
(11.3) (3.1) (10.7) (1.07–12.5) (0.49–2.23) (0.98–12.6)
MMP12 282A.G (rs2276109)
AA 507 283 356 1.06 0.83 1.28 PA=0.42 PA=0.18 PA=0.29
(9.3) (8.8) (11.2) (0.92–1.23) (0.73–0.95) (1.10–1.50)
AG 98 48 53 1.25 1.14 1.09 PD=0.57 PD=0.07 PD=0.29
(10.1) (8.1) (8.9) (0.88–1.76) (0.82–1.60) (0.74–1.62)
GG 6 5 2 0.59 1.58 0.43 PR=0.31 PR=0.50 PR=0.16
(9.2) (15.8) (6.1) (0.18–1.94) (0.32–7.81) (0.08–2.25)
MMP12 N122S (rs652438)
AA 483 261 315 1.10 0.92 1.20 PA=0.62 PA=0.40 PA=0.43
(9.4) (8.5) (10.2) (0.95–1.28) (0.80–1.06) (1.02–1.42)
AG 108 62 83 1.04 0.74 1.41 PD=0.56 PD=0.22 PD=0.60
(9.7) (9.3) (13.1) (0.76–1.42) (0.56–0.99) (1.01–1.96)
GG 11 9 5 0.72 1.01 0.71 PR=0.36 PR=0.80 PR=0.32
(10.2) (14.2) (10.1) (0.30–1.74) (0.35–2.91) (0.24–2.11)
PA=P-value for additive genetic model, PD=P-value for dominant genetic model, PR=P-value for recessive genetic model.
*P-value for gene-by-treatment interaction.
CHL, chlorthalidone treatment group; AML, amlodipine treatment group; LIS, lisinopril treatment group.
doi:10.1371/journal.pone.0023609.t007
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that, although unmeasured population substructure may be
present, it is unlikely that the HW disequilibrium in some ethnic
subgroups is driving our suggestive results.
MMP-9 may have a direct effect on plaque destabilization and
may also serve as a biomarker predictive of mortality in patients
with CVD [16]. As previously mentioned, elevated MMP-9 levels
have been observed following acute coronary events [5]_EN-
REF_16. However, Johnson et al. suggested MMP-9 is activated
during healing processes as opposed to causing rupture of plaques
[31]. Based on our findings, chlorthalidone and amlodipine could
potentially influence MMP-9 function. Chlorthalidone, a thiazide-
like diuretic, acts on the Na
+Cl
2 symporter in the kidney, leading
to greatly increased sodium and chloride excretion [32,33].
Chlorthalidone’s antihypertensive mechanism is not fully under-
stood, and we are not aware of studies evaluating independent
effects of chlorthalidone on MMP activity. However, Seeland et al.
examined the effects of diuretic therapy in combination with an
ACE inhibitor and found supplemental treatment with the diuretic
furosemide did not provide additional benefit on extracellular
matrix remodeling compared to ACE inhibitor alone [34].
Amlodipine is a CCB of the dihydropyridine class. It inhibits
vascular smooth muscle contractions, causing increased blood flow
to the heart and decreased peripheral arterial resistance and blood
pressure [35]. Zervoudaki et al. reported that amlodipine increases
plasma MMP-9 levels in hypertensive patients [8,9]. However, a
study involving lercanidipine (another dihydropyridine CCB)
found decreased MMP-9 activity in hypertensives and suggested
a mechanism involving the antioxidant effects of lercanidipine,
which are shared by amlodipine [10]. A possible explanation for
this discrepancy is that the amlodipine study used ELISA to
measure MMP-9 level, whereas the more recent lercanidipine
study used gel zymography [10]. Like other ACE inhibitors,
lisinopril blocks the production of angiotensin II (a vasoconstric-
tor), thereby decreasing blood pressure. Like the MMPs, ACE is a
zinc-dependent endopeptidase [11]. Studies have shown that ACE
inhibition may also inhibit MMP levels [11,12,13,14,36,37,38].
Yamamoto et al. identified two potential interaction mechanisms
Table 8. Pharmacogenetic effects of MMP genetic variants on CHF.
Number of events (event rate per
1000 p-y)
Genotype-specific treatment effects:
Hazard Ratio (95% CI) Pharmacogenetic effects*
Genotype CHL AML LIS C vs. A C. vs. L L vs. A C vs. A C. vs. L L vs. A
MMP9 R279Q (rs17576)
AA 359 283 239 0.73 0.90 0.82 PA=0.53 PA=0.41 PA=0.29
(13.1) (17.8) (14.5) (0.63–0.86) (0.76–1.06) (0.69–0.97)
AG 346 281 255 0.73 0.77 0.95 PD=0.68 PD=0.20 PD=0.38
(11.9) (16.2) (15.5) (0.63–0.86) (0.65–0.90) (0.80–1.13)
GG 97 95 70 0.61 0.82 0.75 PR=0.26 PR=0.92 PR=0.35
(12.4) (20.2) (15.2) (0.46–0.81) (0.60–1.11) (0.55–1.03)
MMP9 R668Q (rs2274756)
GG 591 463 403 0.74 0.85 0.87 PA=0.57 PA=0.59 PA=0.76
(12.8) (17.3) (15.0) (0.65–0.83) (0.75–0.97) (0.76–0.99)
GA 192 175 149 0.67 0.75 0.90 PD=0.34 PD=0.33 PD=0.93
(11.5) (17.2) (15.4) (0.55–0.82) (0.60–0.93) (0.72–1.12)
AA 17 19 14 0.57 0.83 0.69 PR=0.49 PR=0.97 PR=0.49
(11.5) (20.1) (13.8) (0.30–1.10) (0.41–1.68) (0.35–1.37)
MMP12 282A.G (rs2276109)
AA 628 546 467 0.67 0.78 0.86 PA=0.05 PA=0.040 PA=0.15
(11.6) (17.3) (14.9) (0.60–0.76) (0.69–0.88) (0.76–0.98)
AG 154 99 96 0.95 0.98 0.97 PD=0.015 PD=0.044 PD=0.77
(16.0) (17.0) (16.4) (0.74–1.22) (0.76–1.26) (0.73–1.28)
GG 14 9 0.77 3.76 0.21 PR=0.83 PR=0.048 PR=0.07
(22.4) (28.8) (6.1) (0.33–1.78) (0.85–16.6) (0.04–0.95)
MMP12 N122S (rs652438)
AA 639 522 450 0.72 0.84 0.86 PA=0.98 PA=0.41 PA=0.55
(12.5) (17.3) (14.8) (0.64–0.81) (0.75–0.95) (0.76–0.97)
AG 131 108 96 0.72 0.77 0.93 PD=0.90 PD=0.37 PD=0.46
(11.7) (16.4) (15.2) (0.55–0.92) (0.59–1.00) (0.70–1.22)
GG 14 12 12 0.68 0.52 1.31 PR=0.84 PR=0.24 PR=0.34
(12.9) (19.2) (24.8) (0.31–1.46) (0.24–1.13) (0.59–2.91)
PA=P-value for additive genetic model, PD=P-value for dominant genetic model, PR=P-value for recessive genetic model.
*P-value for gene-by-treatment interaction.
CHF; chronic heart failure; CHL, chlorthalidone treatment group; AML, amlodipine treatment group; LIS, lisinopril treatment group.
doi:10.1371/journal.pone.0023609.t008
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was shown to be stabilized in the active site by specific hydrogen
bonds, and its hydrophobic group interacted preferentially with
the S1 site compared to the S19 site [38]. In their subsequent work,
Yamamoto et al. and Takai et al. also found that different ACE
inhibitors show differential binding affinities for MMP-9
[13,36,37,38]. Sakata et al. observed that ACE inhibition directly
lowers MMP activity in rats, thus preventing left ventricular
remodeling [39]. The MMP9 R279Q polymorphism is a
glutamine to arginine substitution located in the catalytic domain
of MMP-9 [16,20] and may affect substrate binding [16]. The
MMP9 R668Q polymorphism is in the hemopexin-like domain
and probably also functions in substrate binding, since removal of
this domain disables the cleavage of triple-helix collagen [19].
MMP-12 is expressed in macrophages and epithelial cells and
has been implicated in the progression of atherosclerosis, wound
repair, and certain cancers [40,41]. Like MMP-9, MMP-12
activity is increased following vascular injury [42]. Plasma MMP-
12 levels are increased in patients with coronary artery disease and
may, therefore, be an independent risk factor for coronary artery
disease [43]. Morgan et al. observed higher MMP-12 levels in
thin-cap atherosclerotic plaques (those considered more prone to
rupture) versus thick-cap plaques. MMP-12 levels were also
elevated in already ruptured plaques, suggesting that MMP-12 has
a role in plaque stability [44]. Based on our findings, chlorthal-
idone, lisinopril, and amlodipine could potentially affect MMP-12
activity. To our knowledge, studies have not evaluated the effects
of diuretics, ACE inhibitors, or CCBs on MMP-12. However,
based on the finding that lercanidipine may inhibit macrophage
function and the fact that macrophages secrete MMP-12, we
hypothesize that CCBs may decrease MMP-12 levels [40,45]. The
MMP12 282A.G polymorphism lies in the MMP12 gene
promoter [15]. The MMP12 282A.G polymorphism affects
AP-1 binding affinity, with the A allele showing a higher affinity
for the protein and, therefore, higher MMP12 promoter activity
[15,18]. MMP12 N122S is an asparagine to serine substitution
located in the coding region of the MMP12 hemopexin domain,
which is responsible for gene activity [17,18]. To our knowledge,
no pharmacogenetic studies have been done on this combination
of polymorphisms, drugs, and outcomes.
Our data suggest associations between the MMP9 R279Q
polymorphism and stroke and between the MMP12 N122S
polymorphism and combined CHD. The MMP9 R279Q
polymorphism has been associated with increased intima-media
thickness [46], an independent predictor of MI and stroke risk
[47]. Blankenberg et al. found that MMP9 R279Q had no effect
on plasma MMP-9 concentration but was associated with future
cardiovascular events in patients with stable angina [16]. This
polymorphism also influences aortic stiffness, which is a determi-
nant of cardiovascular risk [48]. We also found a pharmacogenetic
effect of the MMP9 R668Q polymorphism to increased stroke risk,
although this association may be due to the small number of events
(17 in the chlorthalidone group, 3 in the amlodipine group). The
MMP12 282A.G polymorphism has been associated with
coronary atherosclerosis [15,49,50]. A study by Jormsjo et al.
suggests this polymorphism is associated with narrowing of
coronary arteries in diabetic patients with CHD [15,50].
GenHAT is an ancillary study of ALLHAT. The ALLHAT
study population included only those over age 55 with hyperten-
sion. As a result, our findings may not be generalizable to younger
age groups. An additional limitation is that we looked at only four
MMP polymorphisms. There may be unknown polymorphisms in
these genes or combinations of polymorphisms affecting the
findings. Since we performed multiple tests of pharmacogenetic
effects, these findings would not meet the threshold of statistical
significance if corrected for multiple testing (Bonferroni correction:
0.05/72 tests would equate to a P-value of 0.0007). However,
given the possibility of linkage disequilibrium between variants and
non-mutually exclusive outcomes, this threshold is overly conser-
vative. Nevertheless, the likelihood that these findings are false
positives is not negligible, and independent replication is
necessary. At this time, there are no other large clinical trials
that are outcome-based like ALLHAT in which results can be
replicated. Our findings and the findings of other studies suggest
that future studies might fruitfully investigate the functional
interactions of MMP-9 and MMP-12 with diuretics, ACE
inhibitors, and CCBs. This study has several strengths. The
ALLHAT trial was a large, double-blind randomized trial.
Additionally, the study population showed exceptional ethnic
and gender diversity (about 50% non-White, about 50% female)
[26]. Our results were not sensitive to departures from HWE in
various ethnic groups.
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